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Abnormal activation of the epidermal growth factor receptor (EGFR) and its homolog HER2 (Neu/ErbB2) 
has been associated with many human cancers, and monoclonal antibodies targeting EGFR and HER2 are 
effective anticancer therapies. Structural studies of these receptors and antibodies have revealed much 
about how they function. In this issue of Cancer Cell, Schmiedel et al. report structural and functional studies 
of the anti-EGFR monoclonal antibody Matuzumab. They show that Matuzumab binds and inhibits EGFR 
in a manner distinctive from that of other therapeutic anti-EGFR antibodies and suggest that combination 
therapies with Matuzumab and other antibodies may prove beneficial.The epidermal growth factor receptor 
(EGFR/ErbB1/HER1) consists of an extra-
cellular ligand binding region followed 
by a single membrane-spanning helix, a 
cytoplasmic tyrosine kinase domain, and 
a C-terminal tail of ~230 amino acids (Bur-
gess et al., 2003). Ligand binding to the 
extracellular region promotes receptor 
dimerization, which in turn leads to acti-
vation of the cytoplasmic tyrosine kinase 
(Holbro and Hynes, 2004). When acti-
vated, the EGFR kinase phosphorylates 
several tyrosines in the EGFR C-terminal 
tail that then serve as docking sites for 
downstream signaling effectors that initi-
ate signaling cascades and stimulate cell 
growth and differentiation (Holbro and 
Hynes, 2004). Three EGFR homologs, 
HER2 (Neu/ErbB2), HER3 (ErbB3), and 
HER4 (ErbB4) are found in humans and, together with EGFR, make up the EGFR/
ErbB family of receptors. HER2 is an 
atypical member of this family in that 
it is not directly activated by ligand but 
rather serves as a universal heterodimeric 
partner for each of the other ErbB family 
members (Holbro and Hynes, 2004).
EGFR was the first cell-surface recep-
tor to be associated with cancer, and 
abnormal EGFR or HER2 function has 
subsequently been found to contribute 
to the severity of many human tumors 
(Hynes and Lane, 2005). For this reason, 
agents targeting EGFR or HER2 have 
been actively pursued as cancer thera-
pies. These agents fall into two general 
classes: monoclonal antibodies, which 
bind to receptor extracellular regions 
and will be discussed here, and small-
molecule kinase inhibitors that target the Cancercytoplasmic kinase activity. To date, two 
monoclonal antibodies against EGFR, 
Cetuximab (Erbitux) and Panitumumab 
(Vectibix), have been approved by the 
FDA for treatment of colorectal and/or 
head-and-neck cancer, and two EGFR 
kinase inhibitors, erlotinib (Tarceva) and 
gefitinib (Iressa), have been approved for 
the treatment of lung cancer. A mono-
clonal antibody targeting HER2, Tras-
tuzumab (Herceptin), and a pan-ErbB 
kinase inhibitor, lapatinib (Tykerb), have 
also been approved for treatment of 
HER2-overexpressing breast cancers. 
Many other ErbB-targeted therapies are 
under development.
Beginning ~5 years ago, X-ray crystallo-
graphic studies of the extracellular regions 
of ErbB family members uncovered the 
basic mechanism by which ligand binding  Cell 13, April 2008 ©2008 Elsevier Inc. 291
Cancer Cell
Previewsregulates receptor dimeriza-
tion and activity (Burgess et 
al., 2003) (Figure 1A). The 
extracellular regions of ErbB 
family members are com-
posed of four subdomains. 
Domains I and III are homolo-
gous, and both contribute to 
ligand binding. Domains II and 
IV are homologous and form 
extended, cysteine-rich struc-
tures (Burgess et al., 2003). 
In the absence of ligand, an 
extended loop from domain 
II contacts a pocket at the C 
terminus of domain IV and 
constrains the extracellular 
region to a compact, “teth-
ered” conformation in which 
domains I and III are held far 
apart (Figure 1A, left panel). 
To bind ligand with high affin-
ity, a domain rearrangement 
occurs in which the domain 
II/IV contact is broken and 
domains I and II rotate as a 
pair to bring domains I and III 
into proximity and allow them 
to bind ligand simultaneously 
in a clamp-like interaction 
(Figure 1A, middle panel). In 
this ligand-bound, extended 
structure, the domain II loop 
that contacted domain IV in 
the absence of ligand becomes exposed 
and mediates receptor dimerization (Fig-
ure 1A, middle and right panels). This 
loop is, thus, frequently referred to as the 
“dimerization arm.”
It came as a pleasing surprise when 
crystal structures of the HER2 extracel-
lular region showed that it does not adopt 
the tethered conformation. Instead, HER2 
is fixed in an active-like conformation 
characterized by an interaction between 
domains I and III and a constitutively 
exposed dimerization arm (Cho et al., 
2003; Garrett et al., 2003) (Figure 1B). 
This domain I/III interaction occludes the 
canonical ErbB ligand-binding surface 
and appears to mimic the effects of ligand 
binding, which rationalizes the absence of 
a HER2 ligand and the role of HER2 as 
a universal partner for other ErbB family 
members.
Given the long time scale of clinical tri-
als, many ErbB-targeted therapies entered 
development long before the molecular 
underpinnings of ErbB activation and 
HER2 behavior became apparent. It has, 
thus, been particularly satisfying that as 
structural and biochemical studies of 
therapeutic anti-ErbB antibodies prog-
ress, a consistent picture of ErbB function 
is emerging. For example, Trastuzumab 
(Herceptin) binds to the juxtamembrane 
region of HER2 (Figure 1C) at a site that 
would not obviously interfere with HER2 
dimerization or activation (Cho et al., 
2003). Indeed, biochemical studies show 
that Trastuzumab does not block either 
dimerization or activation of HER2 (Agus 
et al., 2002). Trastuzumab does block 
proteolytic cleavage of the HER2 ectodo-
main, however, which occurs adjacent 
to the cell membrane and leaves behind 
an active kinase, and this effect may 
contribute to its antiproliferative activity 
(Baselga et al., 2001). Antibody-depen-
dent cellular cytotoxicity also appears to 
contribute significantly to Trastuzumab 
activity (Clynes et al., 2000). In contrast, 
the anti-HER2 antibody Pertu-
zumab, currently in phase III 
clinical trials for ovarian can-
cer, binds directly to the HER2 
dimerization arm and blocks 
both dimerization and activa-
tion in response to stimulation 
of a HER2 partner (Agus et al., 
2002) (Figure 1C). This differ-
ence appears to explain why 
Pertuzumab is more effective 
than Trastuzumab in cancers 
where HER2 is activated, but 
not overexpressed.
Unlike HER2, targeting the 
dimerization arm of EGFR 
does not appear to be an 
effective strategy as it is gen-
erally buried at either an intra- 
or intermolecular interface. 
Indeed, the first anti-EGFR 
antibody to be approved by 
the FDA for cancer therapy, 
Cetuximab (Erbitux), com-
petes with ligand for bind-
ing to EGFR and was shown 
by Ferguson and colleagues 
to bind and block the ligand 
binding site on EGFR domain 
III (Li et al., 2005) (Figure 1C). 
These authors also noted that 
Cetuximab binding to EGFR 
would sterically prohibit EGFR 
adopting the extended, active-
like conformation (Figure 1), providing a 
dual mechanism of EGFR inhibition. The 
humanized anti-EGFR antibody IMC-11F8 
binds at this same site and also works by 
this dual mechanism (Li et al., 2008).
In this issue of Cancer Cell, Schmiedel 
et al. now show that a third anti-EGFR 
mAb, Matuzumab, binds at a nearby but 
distinct site on EGFR and displays a dif-
ferent constellation of biochemical and 
inhibitory properties (Schmiedel et al. 
2008). Matuzumab, which is currently in 
phase II trials for treatment of lung and 
stomach cancer, is like Cetuximab in that 
it binds to domain III of EGFR (Figure 1C). 
Unlike Cetuximab, however, the Matu-
zumab binding site does not overlap with 
the EGF binding site, and Matuzumab 
does not completely compete with EGF 
for binding to EGFR. Matuzumab does 
reduce the apparent affinity of EGF for 
EGFR. How to explain this behavior? 
Schmiedel et al. point out that although 
Matuzumab and EGF could simultane-
figure 1. surface Representations of eGfR and HeR2 in Active, 
Inactive, and Antibody-Bound conformations
(A) A surface representation of the extracellular region of EGFR in the ab-
sence of ligand is shown with domains I (blue), II (green), III (yellow), and IV 
(red) colored as indicated (left panel). Ligand (EGF, purple) binding stabilizes 
a domain rearrangement in which domains I and II rotate as a pair and break 
the domain II/IV contact, bringing domain I (blue) and III (yellow) into proxim-
ity to bind ligand. This rearrangement exposes the previously buried domain 
II dimerization arm, which is marked with a red asterisk (middle panel). The 
exposed dimerization arm then mediates receptor dimerization and activation 
(right panel). 
(B) The HER2/ErbB2 extracellular region adopts a constitutively “active-like” 
structure in which domains I and III contact each other directly and the do-
main II dimerization arm is exposed. 
(C) The Fab fragments of Matuzumab (slate blue) bound to EGFR (far left), 
Cetuximab (purple) bound to EGFR (second from left), Trastuzumab (cyan) 
bound to HER2 (second from right), and Pertuzumab (magenta) bound to 
HER2 (far right) are shown. The plasma membrane is indicated with two green 
lines, and a membrane-spanning region is represented with a green cylinder. 
A surface representation of the EGFR kinase is shown in light green with a 
space-filling representation of a bound nucleotide.292 Cancer Cell 13, April 2008 ©2008 Elsevier Inc.
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Previewsously bind to EGFR domain III, the bind-
ing of Matuzumab would interfere with 
formation of the active-like EGFR confor-
mation (Figure 1A, middle panel). Thus, in 
the presence of Matuzumab, EGF could 
only contact domain III (or domain I), and 
its affinity for EGFR would be reduced—
exactly what is observed. Schmiedel et 
al. also show that Cetuximab and Matu-
zumab do not compete for binding to 
EGFR, as predicted from comparison of 
crystal structures of their complexes with 
EGFR, and suggest that combination 
therapy with Cetuximab (or IMC-11F8) 
and Matuzumab may result in added clini-
cal benefit.
It is clear that basic and clinical studies 
of the ErbB family of receptors have come 
a long way in the last few years. The results RanBP2 is a remarkably large (350 kD!) 
protein that contains, as its only enzy-
matic function, an unusual SUMO E3 
ligase domain (Pichler et al., 2002). In 
the final step of SUMO modification, the 
E2 conjugating enzyme Ubc9 transfers 
activated SUMO moieties to lysines on 
substrate proteins. This reaction typi-
cally requires, or is greatly stimulated by, 
SUMO E3 ligases. The best understood 
SUMO E3s are the PIAS family of pro-
teins, which contain a RING finger motif 
and promote sumolyation by recruiting 
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and how to treat ErbB-involved diseases. 
It is also clear that much remains to be 
learned, and exciting times are ahead.
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